These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 26121086)

  • 1. Mutational dynamics between primary and relapse neuroblastomas.
    Schramm A; Köster J; Assenov Y; Althoff K; Peifer M; Mahlow E; Odersky A; Beisser D; Ernst C; Henssen AG; Stephan H; Schröder C; Heukamp L; Engesser A; Kahlert Y; Theissen J; Hero B; Roels F; Altmüller J; Nürnberg P; Astrahantseff K; Gloeckner C; De Preter K; Plass C; Lee S; Lode HN; Henrich KO; Gartlgruber M; Speleman F; Schmezer P; Westermann F; Rahmann S; Fischer M; Eggert A; Schulte JH
    Nat Genet; 2015 Aug; 47(8):872-7. PubMed ID: 26121086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
    Carlsson E; Krohn K; Ovaska K; Lindberg P; Häyry V; Maliniemi P; Lintulahti A; Korja M; Kivisaari R; Hussein S; Sarna S; Niiranen K; Hautaniemi S; Haapasalo H; Ranki A
    Genes Chromosomes Cancer; 2013 Feb; 52(2):191-201. PubMed ID: 23097141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
    Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
    Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
    [No Abstract]   [Full Text] [Related]  

  • 4. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
    Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
    PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
    Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
    Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
    Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
    Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration.
    Po'uha ST; Le Grand M; Brandl MB; Gifford AJ; Goodall GJ; Khew-Goodall Y; Kavallaris M
    Br J Cancer; 2020 Feb; 122(3):434-444. PubMed ID: 31806880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
    Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
    Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
    Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
    Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.
    Naraparaju K; Kolla V; Zhuang T; Higashi M; Iyer R; Kolla S; Okawa ER; Blobel GA; Brodeur GM
    Oncotarget; 2016 Mar; 7(13):15977-85. PubMed ID: 26895110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
    Molenaar JJ; Koster J; Zwijnenburg DA; van Sluis P; Valentijn LJ; van der Ploeg I; Hamdi M; van Nes J; Westerman BA; van Arkel J; Ebus ME; Haneveld F; Lakeman A; Schild L; Molenaar P; Stroeken P; van Noesel MM; Ora I; Santo EE; Caron HN; Westerhout EM; Versteeg R
    Nature; 2012 Feb; 483(7391):589-93. PubMed ID: 22367537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of ALK hotspot mutations in relapsed neuroblastoma.
    Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
    Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
    Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
    Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrence.
    Jones RA; Moorehead RA
    Genes Chromosomes Cancer; 2019 Jun; 58(6):381-391. PubMed ID: 30597648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
    Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
    Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of new ALK mutations at relapse of neuroblastoma.
    Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
    J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.
    Modena P; Lualdi E; Facchinetti F; Veltman J; Reid JF; Minardi S; Janssen I; Giangaspero F; Forni M; Finocchiaro G; Genitori L; Giordano F; Riccardi R; Schoenmakers EF; Massimino M; Sozzi G
    J Clin Oncol; 2006 Nov; 24(33):5223-33. PubMed ID: 17114655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
    Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
    Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.